Pexels.com
Six drugs were recalled in June to protect patients from possible harmful defects associated with the products, the U.S. Food and Drug Administration reported.
Such recalls are voluntary actions carried out by drug makers to remove potentially defective medicines from the market, the FDA said. They may be initiated either by the manufacturer or the FDA.
---
Drug Recalls for June
| Date | Brand Name | Product Description | Reason/ Problem | Company |
| June 28 | PharMEDium | 0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe | The electronic customer ordering system stated it is sulfite-free, but the product contains sulfite. | PharMEDium Services LLC |
| June 26 | Macleods | Losartan Potassium USP tablets and Losartan Potassium/Hydrochlorothiazide combination tablets | Presence of NMBA impurity | Macleods Pharmaceutical Limited |
| June 20 | Infusion Options Inc. | All sterile products within expiry | Lack of Sterility Assurance | Infusion Options Inc. |
| June 18 | Premier Pharmacy Labs | All products intended to be sterile | Lack of Sterility Assurance | Premier Pharmacy Labs Inc. |
| June 18 | RXQ Compounding LLC | All sterile human and animal products within expiry | Lack of Sterility Process Assurance | RXQ Compounding LLC |
| June 11 | GSMS Inc. | Losartan potassium tablets | Detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) | Teva Pharmaceuticals USA Inc. |
